Lipoprotein(a) is causally associated with an increased risk of atherosclerotic cardiovascular disease and calcific aortic valve stenosis.1 Clinical trials of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody inhibitors have shown that higher versus lower concentrations of lipoprotein(a) increase the risk of initial and recurrent cardiovascular events, and modest reductions in lipoprotein(a) concentrations of 20–25% are accompanied by larger absolute reductions in cardiovascular risk.
Kaynak: The Lancet
